Kristen Fortney, BioAge Labs CEO
December 18, 2024 09:00 AM EST
Deals
Pharma

No­var­tis turns to BioAge for new tar­gets based on longevi­ty and ex­er­cise

Kyle LaHucik

Senior Reporter

BioAge Labs, which be­gan near­ly a decade ago as an an­ti-ag­ing biotech and then turned to obe­si­ty this year, is go­ing back to its roots …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

No­vo Nordisk part­ners with Broad In­sti­tute spin­out Pho­tys af­ter the star­tup's lay­offs

Mer­ck’s long-await­ed obe­si­ty move is an oral GLP-1 from Chi­na

Ex­clu­sive: In­sitro makes head­way on the hard­er road, dis­cov­er­ing new ALS drug tar­get

Flag­ship gene ther­a­py start­up Ring Ther­a­peu­tics near­ly halves work­force in lat­est job cuts

SiteOne Ther­a­peu­tics, a pain biotech that's part­nered with Ver­tex, nabs $100M

Au­ri­on’s eye cell ther­a­py im­proves vi­sion in small study, plots Phase 3 tri­al

A service from the Financial Times